Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signaling
pathway (VSP) have been important additions in the therapy of various cancers, especially …

BACKGROUND: Interfering with angiogenesis is an effective, widely used approach to
cancer therapy, but antiangiogenic therapies have been associated with important systemic …

Clinical outcomes for patients with a wide range of malignancies have improved
substantially over the last two decades. Tyrosine kinase inhibitors (TKIs) are potent …

Novel cancer therapies targeting tumor angiogenesis have revolutionized treatment options
in a variety of tumors. Specifically, VEGF signaling pathway (VSP) inhibitors have been …

Recognition and management of treatment-related cardiovascular toxicity, defined as either
an acute cardiac event or a chronic condition, has been tightly integrated into routine cancer …

The vascular endothelial growth factor (VEGF) signaling pathway (VSP) fulfills a cardinal
role in endothelial cells and its inhibition has profound cardiovascular impact. This is true not …

Vascular Endothelial Growth Factor (VEGF) is considered to be one of the most important
regulators of angiogenesis and a new key target in anti-cancer treatment. Various clinical …

Abstract Learning Objectives After completing this course, the reader will be able to:
Promptly recognize cardiovascular adverse events associated with anti-VEGF therapy in …

The development of new therapies for cancer has led to dramatic improvements in
survivorship. Angiogenesis inhibitors represent one such advancement, revolutionising …

Anti-angiogenic targeted therapies are now major tools in the management of solid tumors.
Briefly, one can distinguish between monoclonal antibodies such as bevacizumab directed …